EDP-305 is a small molecule commercialized by Enanta Pharmaceuticals, with a leading Phase II program in Non-Alcoholic Steatohepatitis (NASH). According to Globaldata, it is involved in 10 clinical trials, of which 9 were completed, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of EDP-305’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for EDP-305 is expected to reach an annual total of $88 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
EDP-305 Overview
EDP-305 is under development for the treatment of non-alcoholic steatohepatitis (NASH). The drug candidate is a steroidal non-carboxylic acid, modified with additional non-steroidal binding element to enhance potency. It is administered through oral route formulated as tablet and suspension. The drug candidate acts by targeting farnesoid X-activated receptor. It was under development for the treatment of non-alcoholic fatty liver disease (NAFLD) and primary biliary cirrhosis.
Enanta Pharmaceuticals Overview
Enanta Pharmaceuticals (Enanta) is a biotechnology company. It discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Enanta also develops EDP-938, a potent N-protein inhibitor for the respiratory syncytial virus; and programs to discover and develop chemical entities for the treatment of the hepatitis B virus. The company also develops and markets protease inhibitor compounds for the treatment of the hepatitis C virus through collaborative development and license agreement with AbbVie. Enanta is headquartered in Watertown, Massachusetts, the US
The company reported revenues of (US Dollars) US$86.2 million for the fiscal year ended September 2022 (FY2022), a decrease of 11.2% over FY2021. The operating loss of the company was US$123.8 million in FY2022, compared to an operating loss of US$109.6 million in FY2021. The net loss of the company was US$121.8 million in FY2022, compared to a net loss of US$79 million in FY2021.
The company reported revenues of US$23.6 million for the first quarter ended December 2022, an increase of 16.1% over the previous quarter.
For a complete picture of EDP-305’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
